References
- Ambudkar S V, Kimchi-Sarfaty C, Sauna Z E, Gottesman M M. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468–7485
- Wu C P, Calcagno A M, Ambudkar S V. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 2008; 1: 93–105
- Arceci R J, Stieglitz K, Bierer B E. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992; 80: 1528–1536
- Shang S, Seedhouse C, Russell N, Pallis M. Low dose rapamycin does not modulate p-glycoprotein function in acute myeloid leukaemia. Leuk Res 2008; 32: 836–837
- Pawarode A, Shukla S, Minderman H, et al. Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother Pharmacol 2007; 60: 179–188
- Polak P, Hall M N. mTOR and the control of whole body metabolism. Curr Opin Cell Biol 2009; 21: 209–218
- Pop I, Pop L M, Gehtie M-A, Vitetta E S. Targeting mammalian target of rapamycin to both downregulate and disable the P-glycoprotein pump in multidrug-resistant B-cell lymphoma cell lines. Leuk Lymphoma 2009; 50: 1155–1162
- Teachey D T, Sheen C, Hall J, et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 2008; 112: 2020–2023
- Figlin R A, Brown E, Armstrong A J, et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw 2008; 6(Suppl 5)S1–S20
- Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008; 17: 1717–1734